Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TILs have a long history in cancer immunotherapy, with demonstration in the 1980s that adoptive transfer of TILs derived from patients' melanoma tumors can lead to cancer regression (145).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [145]
Citations
Cites
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationA New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationMulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationBiological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Self-citationRosenstein, M., Ettinghausen, S. E., & Rosenberg, S. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.5.1735 · Cited by 530
Self-citationMuul, L. M., Spiess, P. J., Director, E. P., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.989 · Cited by 486
Self-citationGrimm, E., Ramsey, K., Mazumder, A., Wilson, D., Djeu, J., & Rosenberg, S. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.3.884 · Cited by 467
Self-citationLotze, M. T. (1986) · JAMA · doi:10.1001/jama.1986.03380220083027 · Cited by 455
Self-citation
Research works printed but not linked: 7
- Rosenberg, 1985, JNCI, 75, 595
- Lafreniere, 1985, Cancer Res, 45, 3735
- Rosenstein, 1984, Cancer Res, 44, 1946
- Spiess, 1987, JNCI, 79, 1067
- Itoh, 1986, Cancer Res, 46, 3011
- Rabinowich, 1987, Cancer Res, 47, 173
- Belldegrun, 1988, Cancer Res, 48, 206
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
“After this first trial of successful adoptive immunotherapy, the team subsequently improved this approach with TILs and demonstrated that the adoptive transfer of TILs expanded in IL-2 showed more therapeutic potency.(58,59) These studies provide a rationale for the use of TILs to treat advanced human cancers.”
BackgroundAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Self-citationChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Self-citation
Metadata
- Authors
- Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., & White, D. E.
- Affiliations
- National Cancer Institute (US)
- National Cancer Institute (MY)
- DuPont (United States) (US)
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1988-12-22
- Volume
- 319
- Issue
- 25
- Pages
- 1676-1680
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2335365056
- Cited by
- 2,389
- References
- 24
- Citations by year
- 2026: 76 · 2025: 95 · 2024: 113 · 2023: 89 · 2022: 106 · 2021: 113 · 2020: 120 · 2019: 86 · 2018: 83 · 2017: 69 · 2016: 67 · 2015: 51 · 2014: 33 · 2013: 40 · 2012: 34
- FWCI
- 30.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic melanoma, tumor-infiltrating lymphocytes, interleukin-2, adoptive immunotherapy, cyclophosphamide, lymphokine-activated killer cells, tumor regression
- MeSH terms
- Adult, Cells, Cultured, Combined Modality Therapy, Cyclophosphamide, Female, Humans, Immunotherapy, Interleukin-2, Lymphocytes, Male, Melanoma, Middle Aged, Neoplasm Metastasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1056/nejm198812223192527
- The paper
- Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., & White, D. E. (1988). Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejm198812223192527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.